The present disclosure relates to monoclonal antibodies anti-FGFR4and their use as medicaments and diagnostic agents. In particular, itrelates to an antibody which specifically binds to the acid box domain ofFGFR4and to specific portions thereof. Nucleic acids coding for said antibody,vectorsand host cells for their expression and production, antibody-drug conjugatesandpharmaceutical compositions comprising said antibody are also within the scopeof the present disclosure. The present disclosure also relates to antibodiesanti-FGFR4for use for detecting, killing, affecting or inhibiting development and/or differentiation of colon cancer stem cells.
